|
Volumn 10, Issue 3, 2010, Pages 239-245
|
Public drug expenditure in the Republic of Ireland
|
Author keywords
Ireland; medicines; patient co payment; pharmacoeconomic assessment; pricing; reimbursement
|
Indexed keywords
ADALIMUMAB;
BETA1A INTERFERON;
ETANERCEPT;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
REFIB;
UNCLASSIFIED DRUG;
GENERIC DRUG;
PRESCRIPTION DRUG;
COMMUNITY;
COST CONTROL;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
DRUG MARKETING;
ECONOMIC EVALUATION;
FUNDING;
HEALTH CARE COST;
HEALTH CARE POLICY;
HEALTH CARE SYSTEM;
HEALTH SERVICE;
IRELAND;
PATENT;
PHARMACY;
PRESCRIPTION;
REIMBURSEMENT;
REVIEW;
COST;
ECONOMICS;
HUMAN;
PHARMACOECONOMICS;
PUBLIC HEALTH;
STATISTICS AND NUMERICAL DATA;
TRENDS;
COST SHARING;
DRUG COSTS;
DRUGS, GENERIC;
ECONOMICS, PHARMACEUTICAL;
HEALTH EXPENDITURES;
HUMANS;
IRELAND;
NATIONAL HEALTH PROGRAMS;
PRESCRIPTION DRUGS;
REIMBURSEMENT MECHANISMS;
|
EID: 77953716138
PISSN: 14737167
EISSN: 17448379
Source Type: Journal
DOI: 10.1586/erp.10.23 Document Type: Review |
Times cited : (30)
|
References (8)
|